Scarica l'app Stockscreener
2.36
0.43%
0.010
Dopo l'orario di chiusura:
2.36
Precedente Chiudi:
$2.35
Aprire:
$2.35
Volume 24 ore:
13,013
Relative Volume:
0.30
Capitalizzazione di mercato:
$20.33M
Reddito:
-
Utile/perdita netta:
$-12.47M
Rapporto P/E:
-0.2659
EPS:
-8.877
Flusso di cassa netto:
$-10.85M
1 W Prestazione:
+0.00%
1M Prestazione:
-1.67%
6M Prestazione:
-42.44%
1 anno Prestazione:
+490.00%
Intervallo 1D:
$2.32
$2.44
Intervallo di 1 settimana:
$2.32
$2.44
Portata 52W:
$2.08
$6.7499
Neurobo Pharmaceuticals Inc Stock (NRBO) Company Profile
Nome
Neurobo Pharmaceuticals Inc
Settore
Industria
Telefono
(857) 702-9600
Indirizzo
545 CONCORD AVENUE, CAMBRIDGE, MA
Confronta NRBO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRBO
Neurobo Pharmaceuticals Inc
|
2.36 | 20.33M | 0 | -12.47M | -10.85M | -2.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neurobo Pharmaceuticals Inc Stock (NRBO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
Neurobo Pharmaceuticals Inc Borsa (NRBO) Ultime notizie
NeuroBo Pharmaceuticals : Reports Third Quarter 2021 Financial ResultsForm 8-K - Marketscreener.com
Reviewing InterCure (NASDAQ:INCR) & NeuroBo Pharmaceuticals (NASDAQ:NRBO) - Defense World
Diabetic Nephropathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | AstraZeneca, NeuroBo Pharma, Don-A ST, MThera Pharma , Grünenthal, Averitas Pharma, Daiichi Sankyo - Barchart
MTVA stock touches 52-week low at $2.04 amid market challenges - Investing.com Canada
MTVA stock touches 52-week low at $2.04 amid market challenges By Investing.com - Investing.com South Africa
NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from Dong-A ST Co., Ltd. - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021 - Marketscreener.com
NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Decides to Discontinue Its Clinical Development of ANA001 (Niclosamide) and Clinical Development of Gemcabene for the Treatment of COVID-19 - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Management Changes - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of NASH - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces Management Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces CEO Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Executive Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces the Appointment of Current Board Member, Hyung Heon ("H.H.") Kim as the Company's President, Principal Executive Officer, and Principal Accounting Officer - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
NeuroBo Pharmaceuticals Announces Management Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Exclusive License Agreement with MThera Pharma Co., Ltd. for NB-01 - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Elects Hyung Heon Kim and Andrew I. Koven to Board of Directors - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces Executive Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NeuroBo Pharmaceuticals Reveals Promising Therapeutic Developments - TipRanks
NeuroBo Pharmaceuticals rebrands to become MetaVia - FiercePharma
NeuroBo rebrands to MetaVia, changes Nasdaq ticker to MTVA By Investing.com - Investing.com Canada
NeuroBo Pharmaceuticals announces relignment, change name - TipRanks
NeuroBo rebrands to MetaVia, changes Nasdaq ticker to MTVA - Investing.com
NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes - TipRanks
Form 8-K NeuroBo Pharmaceuticals, For: Nov 15 - StreetInsider.com
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaViaReflecting the Company's Focus on Cardiometabolic Diseases - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires Shares in NeuroBo Pharmaceuticals Inc - GuruFocus.com
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024 - Smartkarma
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November - cnhinews.com
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz
Finansavisen - Finansavisen
NRBO stock touches 52-week low at $2.55 amid market challenges - Investing.com
NeuroBo Pharmaceuticals Unveils Updated Corporate Presentation - TipRanks
Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation - Simply Wall St
NRBO stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
NRBO stock touches 52-week low at $2.9 amid market challenges - Investing.com India
NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25… - Zacks Small Cap Research
NeuroBo reports positive early trial results for obesity drug By Investing.com - Investing.com South Africa
NeuroBo reports positive early trial results for obesity drug - Investing.com
We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate - Yahoo Finance
Neurobo Pharmaceuticals Inc Azioni (NRBO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):